Page 183 - Read Online

Costa et al. Hepatoma Res 2018;4:35 Hepatoma Research
DOI: 10.20517/2394-5079.2018.06

Original Article Open Access

[ F]FDG PET imaging evaluation on non-alcoholic
18
fatty liver disease and hepatocellular carcinoma

model treated with sorafenib

Fernando Gomes de Barros Costa , José Tadeu Stefano , Daniele de Paula Faria , Caio de Souza Levy ,
1
2
1
1
Maria Cristina Chammas , Camila de Godoi Carneiro , Isabel Veloso Alves Pereira , Bruno Cogliati , Flair
3
4
2
4
José Carrilho , Claudia P. Oliveira 1
1
1 Department of Gastroenterology (LIM-07), University of São Paulo School of Medicine, São Paulo 01246-903, Brazil.
2 Nuclear Medicine Laboratory (LIM-43), Radiology and Oncology Department, University of São Paulo School of Medicine, São
Paulo 01246-903, Brazil.
3 Radiology and Oncology Department, University of São Paulo School of Medicine, São Paulo, São Paulo 01246-903, Brazil.
4 Department of Pathology, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo 05808-010, Brazil.
Correspondence to: Dr. Fernando Gomes de Barros Costa, Department of Gastroenterology (LIM-07), University of São Paulo
School of Medicine, Lim-07 Ave. Dr. Arnaldo, São Paulo 01246-903, Brazil. E-mail: fgbcosta85@gmail.com; Dr. Claudia P.
Oliveira, Department of Gastroenterology (LIM-07), University of São Paulo School of Medicine, Lim-07 Ave. Dr. Arnaldo, São
Paulo 01246-903, Brazil. E-mail: claudia.oliveira220@fm.usp.br
How to cite this article: Costa FGB, Stefano JT, Faria DP, Levy CS, Chammas MC, Carneiro CG, Pereira IVA, Cogliati B, Carrilho FJ,
Oliveira CP. [ F]FDG PET imaging evaluation on non-alcoholic fatty liver disease and hepatocellular carcinoma model treated
18
with sorafenib. Hepatoma Res 2018;4:35. http://dx.doi.org/10.20517/2394-5079.2018.06
Received: 8 Feb 2018 First Decision: 9 Mar 2018 Revised: 11 May 2018 Accepted: 11 May 2018 Published: 12 Jul 2018
Science Editor: Guang-Wen Cao Copy Editor: Jun-Yao Li Production Editor: Cai-Hong Wang

Abstract
Aim: Evaluate the effect of sorafenib in a rat model of non-alcoholic fatty liver disease (NAFLD) related to hepatocellular
carcinoma (HCC) by quantifying the correlation between changes in glucose metabolism on PET imaging and degree of
tumor differentiation.

Methods: NAFLD related HCC was induced by the combination of high fat and choline deficient diet with
diethylnitrosamine (100 mg/L) for 16 weeks. Then carcinogenic stimuli were suspended, liver nodules were identified
by abdominal ultrasound and two groups were randomized: control (n = 10) and sorafenib (n = 20). Rats received daily
18
gavage administration of 1 mL saline or sorafenib (5 mg/kg/day) for more 3 weeks. After treatment, [ F]FDG PET scan
was performed on animals.

18
Results: [ F]FDG uptake was lower in the sorafenib group than that in the control group (3.3 ± 0.48 vs. 5.5 ± 1.5, P = 0.01).
2
Direct correlation was found between poorly-differentiated HCC and TumorSUVmax/MuscleSUVmax ratio (R = 0.54,
P = 0.006). Treatment was associated with significantly more residual tumors that were well differentiated (Grades I/II)
than in the untreated control group (39% vs. 5%, respectively, P = 0.01).

© The Author(s) 2018. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.hrjournal.net